HomeNewsBusinessSpiceJet flies back into the red with April-June net loss rising to Rs 789 crore

SpiceJet flies back into the red with April-June net loss rising to Rs 789 crore

The airline's revenue from operations for April-June came in at Rs 2,457 crore, more than double when compared to Rs 1,090 crore registered in the same period a year ago.

September 01, 2022 / 10:50 IST
Story continues below Advertisement

SpiceJet Ltd fell back into the red in the fourth quarter of 2021-22 (Q4FY22) and in the first quarter of 2022-23 (Q1FY23). The airline reported a net loss of Rs 458 crore and Rs 789 crore, for the quarters ended March and June, respectively.

The low-cost carrier, which reported its Q4FY22 and Q1FY23 results on August 31, had reported a profit of Rs 23 crore in the third quarter of 2021-22 and a loss of Rs 235 crore in the quarter ended March 2020-21 and a loss of Rs 729 crore in the first quarter of 2021-22.

Story continues below Advertisement

SpiceJet had delayed announcing the results of its fourth quarter in 2021-22 due to a ransomware attack.

The total revenue from operations for the January-March quarter came in at Rs 1,865 crore, slightly lower than Rs 1,877 crore reported in the year-ago quarter.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show